Andere talen CervoMed Inc.

Aandelen

CRVO

US15713L1098

Geschatte realtime Cboe BZX Andere beurzen 21:53:18 28-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,39 ^USD	-1,61%		-5,12%	+141,74%

20/05	CervoMed benoemt William Elder CFO	MT
08/04	CERVOMED INC. : Canaccord Genuity herhaalt koopadvies voor het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CervoMed Names William Elder CFO	20/05
CervoMed to Appoint William Elder as Chief Financial Officer	20/05
Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M	15/05
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates	15/05
CervoMed : Nominating and Corporate Governance Committee Charter	06/05
CervoMed : Corporate Presentation April 2024	22/04
CervoMed : Corporate Presentation April 2024	03/04
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	01/04
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
CervoMed to Participate in Upcoming Investor Conferences	28/03
CervoMed Prices $50 Million Equity Sale to Private Investors	28/03
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	28/03
CervoMed Inc. announced that it expects to receive $49.999967 million in funding	28/03
CervoMed : Shareholder Meeting - Form 8-K	18/03
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	05/03
CervoMed to Participate in the BIO CEO and Investor Conference	21/02
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	20/02
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	12/02
Cervomed Inc. Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal That Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	12/02
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CervoMed Inc.

Aandelen

CRVO

US15713L1098

Andere talen

Filters